An experimental study on the effect of felodipine on serum electrolytes and lithium concentration in albino rabbits by Gupta, Ajay K et al.
Gupta et al                                     Journal of Drug Delivery & Therapeutics; 2014, 4(5), 127-131 127 
© 2011-14, JDDT. All Rights Reserved                                                      ISSN: 2250-1177                                          CODEN (USA): JDDTAO 
Available online on 15.09.2014 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
© 2014, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original 
work is properly cited 
 
RESEARCH ARTICLE 
AN EXPERIMENTAL STUDY ON THE EFFECT OF FELODIPINE ON SERUM 
ELECTROLYTESAND LITHIUM CONCENTRATION IN ALBINO RABBITS 
*Dr A K Gupta, Assoc Prof, Dept of Pharmacology, AFMC, Pune 
Dr Anjan Khadka, Resident, Dept of Pharmacology, AFMC, Pune 
Dr A K Sharma, Prof & HOD, Dept of Pharmacology, AFMC, Pune 
Dr Sushil Sharma, Assoc Prof, Dept of Pharmacology, AFMC, Pune 
Dr N Dahiya, Assoc Prof, Dept of Pharmacology, AFMC, Pune 
Dr DBS Brashier, Assoc Prof, Dept of Pharmacology, AFMC, Pune 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Bipolar affective (maniac-depressive) disorder 
is a frequently diagnosed and a very serious psychiatric 
disorder. It is the second most common disorder after 
unipolar major depression.1 It constitutes a major 
percentage of psychiatric morbidity amongst younger 
age group of childhood and adolescence as well as older 
age group of psychiatric patients too. Episodes of mood 
swings characteristics of this disease are generally 
unrelated to life events. Since the exact pathophysiology 
of the disorder is not well known, it poses a perpetual 
challenge to the treating physician. The clinical and 
therapeutic distinction of bipolar disorders prompted 
many researchers to find effective therapy for this 
condition.2 
Lithium carbonate is often referred to as an 
“anti-maniac” drug, but in many parts of the world it is 
also considered as “mood stabilizing” agent too because 
of its primary action of preventing mood swings in 
patients in patients with bipolar affective (maniac-
depressive) disorder.3,4 Lithium salts were introduced 
into psychiatry in 1949 for the treatment of mania.4 
However, its use was based on incorrect hypothesis but 
extremely good fortune of choosing correct dosage.Since 
lithium salts were observed to have a very high toxicity 
and extremely low therapeutic index, when used as a 
substitute for sodium chloride in cardiac disease for 
which its use was discontinued for this purpose.3,4 
However after 1970, once there were convincing 
evidence for both the safety and efficacy of lithium in the 
treatment of mania and prevention of recurrent attacks of 
maniac-depressive disorders, again lithium surfaced in 
pharmacotherapy of bipolar disorders, prompted 
widespread use of lithium for these disorders.3,5,6 
Of recent, since lithium therapy, which requires 
a careful monitoring of serum lithium levels and 
increasing awareness of the side effects of lithium 
therapy, the researchers are prompted to look for 
alternative anti maniac or mood stabilizing agents.3, 7-9 
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ABSTRACT  
Objectives: To study the effect of felodipine, a calcium channel blocker, on concurrent administration with lithium carbonate 
on serum electrolytes and lithium in Albino rabbits. 
Material and Methods: Albino rabbits weighing 2.5 – 3 kg were divided in three group of ten each and were administered 
lithium carbonate and/or felodipine in suspension made of gum tragacanth daily for eight days. Blood was drawn from 
marginal ear vein after 24 hours of first dose and then at 28th day of drug/s administration for acute and chronic effects 
respectively. Serum was separated out and supernatant was decanted after centrifugation at 3000 rpm. Serum sodium, 
potassium and/or lithium were estimated using flame photometry. Heart rate was measured by heart transducer and polygraph. 
Mortality was observed till a week after last dose administration in this study. 
Results:  Acute effects of co-administration of felodipine and lithium resulted in highly significant decrease in heat rate but no 
fall in serum potassium and insignificant increase in sodium levels from the baseline values. On chronic co-administration, 
significant decrease in heat rate was maintained without any significant change in serum electrolytes and lithium levels from 
base line. No mortality was observed in the group treated with felodipine and lithium simultaneously. 
Conclusions: Felodipine with lithium co-administration minimally affect the serum electrolytes and lithium concentration and 
thus appears relatively safe for co-administration.  
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 However lithium salts remains, as main line of 
drug till an alternative drug with least side effects is 
made available for treatment of psychiatric patients 
suffering of bipolar disorders.8, 10 
 Hypertension remains one of the most 
important preventable contributors to disease and death. 
The first line drugs for treatment of hypertension are 
thiazide-type diuretic, calcium channel blockers (CCB), 
angiotensin converting enzyme inhibitors (ACEI), or 
angiotensin receptor blocker (ARB).11Presently CCBs 
are one of the commonly used drugs in management of 
hypertension, coronary heart diseases, and arrhythmias. 
Many new drugs in this group of CCBs were synthesized 
and now a days clinically available for use as 
amlodipine, diltiazem, felodipine, isradipine, 
lacidipine,lercanidipine, nicardipine, nifedipine, 
nisoldipine, verapamil,etc. CCBs promote vasodilator 
activity (and reduce blood pressure) by reducing calcium 
influx into vascular smooth muscle cells by interfering 
with voltage-operated calcium channels (and to a lesser 
extent receptor-operated channels) in the cell 
membrane.
12
 Interference with intracellular calcium 
influx is also important in cardiac muscle, cardiac 
conduction tissue and gastrointestinal smooth muscle.13 
 The coexistence of maniac-depressive 
psychosis (MDP) or bipolar disorder and hypertension is 
well documented fact in clinical medicine.14-16 Under 
such comorbid situations, co-administration of lithium 
carbonate with calcium channel blockers is fairly likely 
as both the drugs are well established and are forerunner 
in their respective fields.(16) However, many reports of 
adverse effects due co-administration are on record. 
Most of these reports have found that lithium toxicity 
gets precipitated in an otherwise stabilized patients 
whenever one of the CCBs were added to the regimen 
for control of hypertension.3,4,17 Such observations led to 
rightful concern amongst the treating physicians while 
using these two drugs simultaneously. Also calcium 
antagonists may be an alternative choice in prophylactic 
treatment for bipolar illness, especially in patients who 
cannot be treated with lithium or carbamazepine.17 
In view of the above, it was felt worthwhile to 
undertake a study to investigate possible effects of co-
administration of lithium carbonate and a commonly 
used CCB (felodipine- a dihydropyridine) on serum 
lithium, sodium and potassium levels besides recording 
one of the cardiovascular parameters- heart rate.  
MATERIALS AND METHODS 
Healthy and adult albino rabbits of New 
Zealand strain weighing between 2.5 – 3.0 kg of either 
sex were used as experimental animals in this study after 
getting approval from Institutional Animal Ethics 
Committee. The rabbits were maintained on standard 
laboratory diet and water at libitum. They were divided 
into two groups of ten each. The drugs were 
administered orally in the morning at a fixed time i.e. 
1000 hour after overnight fasting to eliminate the 
probability of food related or circadian variation. Pure 
lithium carbonate salt was first dissolved in minimal 
amount of hydrochloric acid and further diluted to make 
it to a working concentration of 30 mg/ml for 
administration to rabbits. Also, felodipine, a white 
crystalline compound, which is practically insoluble in 
water, was made into a suspension with 1% gum 
tragacanth, freshly prepared every day for administration 
to rabbits. 
Equipment: A flame photometer model CL26D ELKON 
was used to estimate the serum electrolytes i.e. Na+, K+, 
Li+. Apart from this, a transducer with polygraph was 
used to record heart rate. 
Plan of study: Twenty rabbits were randomly divided 
into two groups of ten each. Group 1 was the control 
group which received only lithium carbonate while group 
2 received both lithium carbonate and felodipine 
together. On day of beginning of the study, heart rate 
record was done using transducer and a polygraph. Also 
blood sample was drawn for baseline study from all the 
twenty animals from marginal ear vein and collected in 
dry and sterile test tube without undue frothing or 
disturbance.18 Subsequently, the tubes were kept 
undisturbed for an hour at room temperature and then 
shifted into the refrigerator maintained at 40C overnight. 
Group 1 animals were administered first dose of Lithium 
carbonate in the dosage 50 mg/kg of body weight with 
gentle restraining in the cage and orogastric infant tube 
passed into stomach, taking due care, to ascertain that 
tube has not got into respiratory tract. Similarly, group 2 
animals were administered both lithium carbonate 50 
mg/kg and felodipine 1.5 mg/kg of body weight in 1% 
gum tragacanth suspension.  
 For acute effects, after 24 hours of first drug 
administration for both groups, the heart rate was 
recorded as well as the blood was collected to do 
estimation of serum electrolytes- Na+& K+ and Li+. The 
drug administration was further continued for 28 days, 
group 1 with lithium carbonate and group 2 with co-
administration of lithium carbonate and felodipine. On 
28th day, heart rate was recorded and blood was collected 
as before to do serum electrolytes- Na+& K+ and Li+ 
estimation. 
 Blood samples was kept overnight in 
refrigerator at 4C and in morning was centrifuged at 
3000 rpm. The supernatant was sequentially put through 
flame photometry with appropriate dilution as per the 
stock solution and sample was analyzed for sodium, 
potassium and where applicable for lithium 
concentration.Animals were observed for further 15 
daysfor any mortality. 
The data was analyzed statistically by student„t‟ test both 
paired and unpaired wherever applicable value. P value < 
0.05 was considered significant. 
RESULTS: 
The mean serum levels of lithium were found to 
be dose dependent. Lithium carbonate produced mean 
serum concentration 0.19±0.04 mEq/L, 0.31±0.02 mEq/L 
and 0.58±0.02 mEq/L at doses of 25, 50 and 75 mg/kg 
respectively after 28th day of oral treatment. Higher 
dosages of lithium - 75mg/kg produced 60% mortality. 
(Table 1) Since doses above 50 mg/kg were found toxic 
to animals, the dose of 50 mg/kg was chosen for 
subsequent interaction studies with felodipine. 
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Table 1: Effects of lithium carbonate on serum lithium concentration and mortality of albino rabbits: 
Dose of oral lithium carbonate (mg/kg) Serum lithium concentration (mEq/L) Number of deaths 
25 0.19±0.04 nil 
50 0.31±0.02 nil 
75 0.58±0.02 6 
All values are mean  SEM. 
Effect of oral lithium carbonate and felodipine 
administration on heart rate of albino rabbits: 
Baseline (pre-treatment) heart rate was 259 ± 2.22 beats 
per minute (bpm). Both lithium carbonateand felodipine 
on concurrent administration with lithium significantly 
decreased the heart rate from 259 2.22 bpm to 244.80 
4.41 bpm and 250±2.14 bpm respectively after 24 hours 
of drug administration. Similarly both lithium carbonate 
and felodipine on concurrent administration with lithium 
decreased the heart rate from 259 2.22 to 213.60 3.45 
bpm and 217±3.16 bpm respectively after 28th day of 
drug administration. This decrease was considered to be 
extremely statistically significant. 
 
Table 2: Effect of oral lithium carbonate alone & oral lithium carbonate and felodipine administration on heart rate of 
rabbits: 
 
Baseline 
(pre-treatment) 
Lithium carbonate  Lithium carbonate and felodipine 
 
Acute effect 
(24hrs) 
Chronic effect 
(28th day) 
 Acute effect 
(24hrs) 
Chronic effect    
(28th day) 
Heart rate 
(bpm) 
259±2.22 242.80±4.40** 213.60±3.45*** 250±2.14** 217±3.16*** 
All values are mean  SEM 
*   P value = <0 .05; ** P value= < 0.01; *** P value = <0.001 
 
Acute effect of oral lithium carbonate alone & oral 
lithium carbonate and felodipine administration on 
serum sodium and potassium: 
The baseline serum sodium was 136.8 ± 1.40 mEq/L. 
After 24 hours of administration of lithium carbonate and 
felodipine on concurrent administration with lithium the 
sodium concentration was found to be 135.80±1.84 
mEq/L and 134±1.65 mEq/L respectively which is 
statistically insignificant reduction (Table 3). 
The baseline serum potassium was 3.44 ± 0.05 mEq/L. 
After 24 hours of administration of lithium carbonate and 
felodipine on concurrent administration with lithium, the 
potassium concentration was found to be 3.44±0.07 
mEq/L and 3.32±0.04 mEq/L respectively which is 
statistically insignificant change(Table 3). 
 
Table 3: Acute effect of oral lithium carbonate alone & oral lithium carbonate and felodipine administration on serum 
sodium and potassium: 
 Baseline 
(pre-treatment) 
Lithium carbonate Lithium carbonate and felodipine 
Acute effect (24hrs) Acute effect (24hrs) 
Sodium conc 
(mEq/L) 
136.8±1.40 135.80±1.84 134±1.65 
Potassium conc 
(mEq/L) 
3.44±0.05 3.44±0.07 3.32±0.04 
All values are mean  SEM 
*   P value = <0 .05; ** P value= < 0.01; *** P value = <0.001 
 
Chronic effect of oral lithium carbonate and felodipine 
administration on serum sodium and potassium: 
The baseline serum potassium was 3.44 ± 0.05 mEq/L. 
On 28th day of drug administration, there was in-
significant increase of serum potassium levels with 
lithium carbonate and felodipine on concurrent 
administration with lithium, from 3.44 0.05 
mEq/L(baseline) to 3.52 0.04 mEq/L and 3.550.02 
mEq/L respectively (Table 4). 
The baseline serum sodium was 136.8 ± 1.40 mEq/L. On 
28th day of drug administration, serum sodium 
concentration was also marginally raised from 136.8 ± 
1.40 mEq/L (baseline) to 139.20 ± 3.52 mEq/L and 
1412.14 mEq/L with lithium carbonate and felodipine 
on concurrent administration with lithium 
respectively(Table 4).All electrolyte changes essentially 
remained statistically in-significant. 
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Table 4: Chronic effect of oral lithium carbonate alone & oral lithium carbonate and felodipine administration on serum 
sodium and potassium: 
 Baseline 
(pre-treatment) 
Lithium carbonate Lithium carbonate and 
felodipine 
Chronic effect (28th day) Chronic effect (28th day) 
Sodium conc 
(mEq/L) 
136.8±1.40 139.20±3.52 141±2.14 
Potassium conc 
(mEq/L) 
3.44±0.05 3.52±0.04 3.55±0.02 
All values are mean  SEM 
*   P value = <0 .05; ** P value= < 0.01; *** P value = <0.001 
 
Effect of oral lithium carbonate alone & oral lithium 
carbonate and felodipine administration on serum 
lithium concentration:  
After 24 hours of drug administration, serum lithium 
levels was 0.31 0.02 mEq/L with oral lithium carbonate 
alone and 0.40  0.06 mEq/L with felodipine on 
concurrent administration with lithium. On 28th day the 
serum lithium concentration was 0.48±0.04 mEq/L and 
0.51±0.03 mEq/L with oral lithium carbonate and 
felodipine on concurrent administration with lithium 
respectively (Table 5). The increment in serum lithium 
concentration with both group was statistically highly 
significant. Mortality was nil after 15 days of observation 
following 28 days of drug treatment. 
 
Table 5: Effect of oral lithium carbonate alone & oral lithium carbonate and felodipine administration on serum lithium 
concentration: 
 Lithium carbonate  Lithium carbonate and felodipine 
 Acute effect 
(24hrs) 
Chronic effect (28th day)  Acute effect (24hrs) Chronic effect (28th day) 
Lithium conc 
(mEq/L) 
0.31±0.02 0.48±0.04** 0.40±0.06 0.51±0.03*** 
All values are mean  SEM 
*   P value = <0 .05; ** P value= < 0.01; *** P value = <0.001 
 
DISCUSSION: 
Lithium carbonate when given orally in 
increasing dose, increased the serum lithium 
concentration with mortality at higher dose i.e. 75 mg/kg. 
The therapeutic dose range of lithium in human being is 
between 0.6-1.25mEq/L. However in this study, blood 
concentration of 0.58mEq/L and above appeared to be 
toxic in albino rabbit. Serum lithium levels were found to 
be 0.31mEq/L in the control group. From these 
observations it seems that felodipine has virtually no 
effect on the same except for decrease in heart rate. In 
addition there was no mortality up to fifteenth day 
following drug therapy. These observations clearly 
indicate that felodipine appears to be safer.  
Many workers have reported decrease in serum 
lithium levels due to concurrent administration of CCBs 
in humans and laboratory animals.(19)Some studies 
showed that lithium clearance were unaffected after 
CCBs administration.4,6,14,20 The mechanism by which 
CCBs change the serum lithium levels is not clearly 
known. It has been postulated that lithium retention is 
related to the increase in sodium excretion associated 
with decreased aldosterone secretion induce by 
CCBs.17,20,21 Any kind of volume depletion has also been 
implicated in precipitating lithium toxicity, since renal 
excretion of lithium depends on sodium balance. Thus 
diuretic effect of CCBs has also been implicated as a 
possible mechanism of this pharmacokinetic 
interaction.17, 21, 22 Lithium reduces the production of 
cyclic adenosine monophosphate (cAMP) and inhibits 
the influx of calcium ion by limiting its channel opening, 
and these may interfere with SA and AV node 
function.22, 23 There is also evidence that hypotensive and 
cardiac-depressant effects of lithium chloride are 
mediated by activation of adenosine triphosphate-
sensitive potassium channels.[24]  Concomitant use of 
diuretics, angiotensin-converting enzyme inhibitors, 
calcium channel antagonists or non-steroidal anti-
inflammatory drugs has been associated with lithium 
toxicity through pharmacokinetic interactions.25,26 A few 
workers have postulated that patient receiving long term 
lithium treatment may be dependent on an intact thirst 
mechanism to maintain a euhydrated state, since such 
prolong therapy has been said to produce nephrogenic 
diabetes insipidus, which is otherwise compensated by 
increased oral intake of water and sodium.27 However, it 
is postulated that CCBs by some mechanism may be 
altering stimulus to thirst and drinking behavior and 
consequent lithium toxicity. In this study, however, no 
effort has been made to elucidate the nature or 
mechanism or the interaction between CCBs and lithium. 
Because lithium alters intracellular calcium ion dynamics 
and lowers platelet [Ca2+] in affectively ill patients but 
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not controls, drugs whose primary action is to modulate 
[Ca2+] in hyperactive cells have been used as antimanic 
agents.28-30There have been many reports of lithium 
toxicity in patients co-administered thiazide diuretics or 
angiotensin converting enzyme inhibitors.31CCBs are 
usually well tolerated and may be useful for a number of 
other psychiatric, neurological and medical conditions. 
CONCLUSION: 
From this study, it may be concluded that as far 
as possible use of CCB should be avoided but in case of 
unavoidable circumstances, it appears safe to use 
felodipine, a dihydropyridine group of CCB amongst all 
others. As this study was conducted in laboratory 
animals, more clinical studies are required before 
arriving at a definitive conclusion. Further study on this 
specific issue is needed to justify such off-label use of 
calcium channel blockers. 
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